Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Jason Sicklick

    Address9500 Gilman Drive #0987
    CA La Jolla 92093
    Phone858-822-6173
    vCardDownload vCard

      Collapse Biography 
      Collapse Awards and Honors
      2016Life Raft Group GIST Clinician of the Year

      Collapse Overview 
      Collapse Overview
      Research
      Gastrointestinal stromal tumors (GIST)
      I am interested in both the role of molecular signaling in the genesis of liver cancers and the study of gastrointestinal stromal tumors (GIST). Currently, my laboratory is investigating: 1) novel allosteric kinase inhibitors to target imatinib-resistant GIST; 2) the role of Hedgehog signaling in the development of GIST; 3) the genomics of wild-type (WT), lacking driver mutations in KIT, PDGFRA, SDHx, or RAS pathway components (KRAS, BRAF, NF-1); 4) the epidemiology of GIST; and 5) novel surgical approaches for GIST (e.g., laparo-endoscopic gastric surgery and intra-operative fluorescence labeling of tumors).

      Primary liver cancer (hepatocellular carcinoma, HCC)
      As a postdoctoral research fellow, my colleagues and I were the first to identify the way in which the Hedgehog signaling pathway regulates liver progenitors, hepatic stellate cells, and human hepatocellular carcinoma. This body of work has been presented at national and international meetings, as well as has been published in peer-reviewed journals. As Hedgehog inhibitors have entered the clinic, this work holds the potential for high impact and translation into clinical trials. We have moved our findings from the bench to the bedside. I am the principal investigator of an investigator-initiated trial titled, “Phase Ib Study of Single Agent Sonidegib, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients with Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis (NCT02151864).” This is the first study of a Hedgehog inhibitor in humans with liver diseases.

      Personalized medicine
      As a clinician-scientist, I am always interested in translating my scientific findings into the clinical care of my patients. With the recent revolution of genomics, many genetic investigations have become technically and fiscally feasible. Our interest in linking genomics with personalized cancer care led to the initiation of a multi-disciplinary molecular tumor board at Moores Cancer Center at UC San Diego Health. In order to apply this approach more rigorously, Dr. Razelle Kurzrock and I are co-principal investigators on a genomic-driven clinical study of 225 patients titled, I-PREDICT (Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy; NCT02534675).

      Profile
      Dr. Jason Sicklick is an assistant professor of Surgery at UC San Diego Health Moores Cancer Center. He is a board-certified general surgeon and surgical oncologist specializing in the treatment of hepatobiliary diseases and sarcomas, including gastrointestinal stromal tumors (GIST). He received his medical degree from the UCLA School of Medicine, he completed his general surgery residency at The Johns Hopkins Hospital, and he completed a fellowship in surgical oncology at Memorial Sloan-Kettering Cancer Center where he was the chief administrative fellow. He joined the Division of Surgical Oncology at Moores Cancer Center in 2010. Dr. Sicklick is an active member of the National Cancer Institute GIST Working Group, the National Comprehensive Cancer Network (NCCN) Hepatobiliary Committee, and the Transatlantic Atlantic Retroperitoneal Sarcoma Working Group. Dr. Sicklick is on the editorial board of Annals of Surgical Oncology, Journal of Gastrointestinal Surgery and Journal of Surgical Research. He is also a member of the numerous societies including the Society of Surgical Oncology, American Society of Clinical Oncology, the American College of Surgeons, American Association for Cancer Research, the Association of Academic Surgery, and the Society for University Surgeons.

      His clinical interests include the treatment of GIST, abdominal/retroperitoneal sarcomas, colorectal and neuroendocrine cancers that have metastasized to the liver, and primary liver tumors. Working with other members of Moores Cancer Center’s Gastrointestinal Cancer Unit and UC San Diego Liver Center, he employs a number of techniques including:
    • Minimally invasive gastric resections of GIST, including laparo-endoscopic resections in collaboration with our minimally invasive surgery team;

    • Organ-sparing sarcoma resections to remove abdominal and retroperitoneal tumors;

    • Parenchymal-sparing liver resections to remove smaller amounts of liver tissue and increase the safety of such operations;

    • Hepatic arterial infusion pump placement for delivery of chemotherapy directly to the liver through a surgically implanted device;

    • Microwave (thermal) ablation-the application of heat to kill tumors;

    • Systemic chemotherapy administered by our medical oncology team;

    • Portal vein embolization to increase the amount of liver remaining after surgical resection performed by our interventional radiology team;

    • Hepatic artery embolization-blockage of blood vessels supplying liver tumors performed by our interventional radiology team;

    • His translational and clinical research focus on molecular mechanisms of GIST and hepatocellular carcinoma, as well as precision medicine approaches to cancer therapy.

      Current Positions
      - Assistant Professor In-Residence, Division of Surgical Oncology, Department of Surgery
      - General Surgery Residency Associate Program Director, Department of Surgery, University of California, San Diego
      - Co-Director for Clinical Collection, Biorepository and Tissue Technology Shared Resource (BTTSR), Moores Cancer Center at UC San Diego Health

      Dr. Igor Koutsenok is a Professor of Practice in Psychiatry. He graduated as a medical doctor in 1983 at the National Medical University in Kiev, (Ukraine). In 1986 he completed his psychiatry residency training and received degree as psychiatrist from the Medical University in Sofia (Bulgaria). In 1993-1996 he worked at the University of London, Department of Addictive Behavior and Psychological Medicine at St. Georges Hospital Medical School, where he completed his Masters Degree in Addiction Psychiatry. In 1997 he was recruited by the University of California San Diego, School of Medicine, Department of Psychiatry and since then he serves as faculty member of the Department. Presently he is a Professor of Psychiatry, Director of the UCSD Center for Criminality and Addiction Research, Training and Application (CCARTA), Co-Director of the South East Asia Addiction Technology Transfer Center and Director of the UCSD-Second Chance Collaborative Behavioral Interventions Program. In 2013 he was appointed as Director of Prevention, Treatment, and Rehabilitation of the United Nations Office on Drugs and Crime, United Nations Office in Vienna, and served the UN until 2016, when he returned to the UCSD. Over the last 20 years Dr. Koutsenok led the design and implementation of the Workforce Development Training series for substance abuse counselors, mental health practitioners, social workers and criminal justice professionals in California and multiple states of the United States. He was the UCSD FACT (Forensic Addiction Treatment Certification) Board of Education Director. Dr. Koutsenok served as of the trainers for the National Drug Court Institute in the USA and provided training and education for judges and members of the judicial system nationwide and internationally. Dr. Koutsenok is also a member of the International Motivational Interviewing Network of Trainers (MINT). For many years Dr. Koutsenok teaches general and addiction psychiatry to medical students, psychiatry residents, psychology trainees, social workers, criminal justice professionals, and policy makers around the world. He has authored and co-authored over 50 scientific publications and 5 book chapters. Dr. Koutsenok has been invited as a presenter and trainer to hundreds of conferences and workshops in the USA and in more than 40 countries around the world.


      Collapse Research 
      Collapse Research Activities and Funding
      Defining the Germline Genomic Landscape of a Novel GIST Multi-tumor Syndrome
      NIH/NCI R21CA192072Mar 4, 2016 - Feb 28, 2018
      Role: Principal Investigator
      Novel Allosteric Kinase Inhibitors Target Imatinib-Resistant GIST
      NIH/NCI K08CA168999Sep 10, 2014 - Aug 31, 2019
      Role: Principal Investigator

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Norton JA, Kim T, Kim J, McCarter MD, Kelly KJ, Wong J, Sicklick J. SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg. 2017 Aug 14. PMID: 28808875.
        View in: PubMed
      2. Milette S, Sicklick J, Lowy AM, Brodt P. MOLECULAR PATHWAYS: TARGETING THE MICROENVIRONMENT OF LIVER METASTASES. Clin Cancer Res. 2017 Jun 14. PMID: 28615370.
        View in: PubMed
      3. Alkhuziem M, Burgoyne AM, Fanta PT, Tang CM, Sicklick J. The Call of "The Wild"-Type GIST: It's Time for Domestication. J Natl Compr Canc Netw. 2017 May; 15(5):551-554. PMID: 28476734.
        View in: PubMed
      4. Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick J, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 May; 15(5):563-573. PMID: 28476736.
        View in: PubMed
      5. Fero KE, Coe TM, Fanta PT, Tang CM, Murphy JD, Sicklick J. Surgical Management of Adolescents and Young Adults With Gastrointestinal Stromal Tumors: A US Population-Based Analysis. JAMA Surg. 2017 Jan 18. PMID: 28114506.
        View in: PubMed
      6. Tang CM, Lee TE, Syed SA, Burgoyne AM, Leonard SY, Gao F, Chan JC, Shi E, Chmielecki J, Morosini D, Wang K, Ross JS, Kendrick ML, Bardsley MR, De Siena M, Mao J, Harismendy O, Ordog T, Sicklick J. Hedgehog pathway dysregulation contributes to the pathogenesis of human gastrointestinal stromal tumors via GLI-mediated activation of KIT expression. Oncotarget. 2016 Oct 25. PMID: 27793025.
        View in: PubMed
      7. Lee CW, Md AI, Schneider DF, Leverson GE, Tran TB, Poultsides GA, Postlewait LM, Maithel SK, Wang TS, Hatzaras I, Shenoy R, Phay JE, Shirley L, Fields RC, Jin LX, Pawlik TM, Prescott JD, Sicklick J, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Weber SM. Minimally Invasive Resection of Adrenocortical Carcinoma: a Multi-Institutional Study of 201 Patients. J Gastrointest Surg. 2016 Oct 21. PMID: 27770290.
        View in: PubMed
      8. Singh AR, Joshi S, Burgoyne AM, Sicklick J, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma. Mol Cancer Ther. 2016 Nov; 15(11):2553-2562. PMID: 27496136.
        View in: PubMed
      9. Sicklick J, Fanta PT, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016 Jun; 35(2):263-75. PMID: 26857926.
        View in: PubMed
      10. Coe TM, Fero KE, Fanta PT, Mallory RJ, Tang CM, Murphy JD, Sicklick J. Population-Based Epidemiology and Mortality of Small Malignant Gastrointestinal Stromal Tumors in the USA. J Gastrointest Surg. 2016 Jun; 20(6):1132-40. PMID: 27025710.
        View in: PubMed
      11. Niemiec SM, Vinetz JM, Sicklick J. Porta Hepatis Mass. JAMA Surg. 2016 Feb 1; 151(2):187-8. PMID: 26630439.
        View in: PubMed
      12. Postlewait LM, Ethun CG, Tran TB, Prescott JD, Pawlik TM, Wang TS, Glenn J, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick J, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Staley CA, Poultsides GA, Maithel SK. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. J Am Coll Surg. 2016 Apr; 222(4):480-90. PMID: 26775162.
        View in: PubMed
      13. Valero-Elizondo J, Kim Y, Prescott JD, Margonis GA, Tran TB, Postlewait LM, Maithel SK, Wang TS, Glenn JA, Hatzaras I, Shenoy R, Phay JE, Keplinger K, Fields RC, Jin LX, Weber SM, Salem A, Sicklick J, Gad S, Yopp AC, Mansour JC, Duh QY, Seiser N, Solorzano CC, Kiernan CM, Votanopoulos KI, Levine EA, Poultsides GA, Pawlik TM. Incidence and Risk Factors Associated with Readmission After Surgical Treatment for Adrenocortical Carcinoma. J Gastrointest Surg. 2015 Dec; 19(12):2154-61. PMID: 26286367.
        View in: PubMed
      14. Murphy JD, Ma GL, Baumgartner JM, Madlensky L, Burgoyne AM, Tang CM, Martinez ME, Sicklick J. Increased risk of additional cancers among patients with gastrointestinal stromal tumors: A population-based study. Cancer. 2015 Sep 1; 121(17):2960-7. PMID: 25930983.
        View in: PubMed
      15. Coe TM, Chang DC, Sicklick J. Small bowel volvulus in the adult populace of the United States: results from a population-based study. Am J Surg. 2015 Aug; 210(2):201-210.e2. PMID: 26002189.
        View in: PubMed
      16. Costa EA, Cunha GM, Smorodinsky E, Cruite I, Tang A, Marks RM, Clark L, Wolfson T, Gamst A, Sicklick J, Hemming A, Peterson MR, Middleton MS, Sirlin CB. Diagnostic Accuracy of Preoperative Gadoxetic Acid-enhanced 3-T MR Imaging for Malignant Liver Lesions by Using Ex Vivo MR Imaging-matched Pathologic Findings as the Reference Standard. Radiology. 2015 Sep; 276(3):775-86. PMID: 25875972.
        View in: PubMed
      17. Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, Sicklick J, Gibbons SJ, Farrugia G, Taguchi T, Gupta A, Rubin BP, Fletcher JA, Ramachandran A, Ordog T. Platelet-Derived Growth Factor Receptor-a Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1. Gastroenterology. 2015 Aug; 149(2):420-32.e16. PMID: 25865047.
        View in: PubMed
      18. Buckel L, Savariar EN, Crisp JL, Jones KA, Hicks AM, Scanderbeg DJ, Nguyen QT, Sicklick J, Lowy AM, Tsien RY, Advani SJ. Tumor radiosensitization by monomethyl auristatin e: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1; 75(7):1376-87. PMID: 25681274.
        View in: PubMed
      19. Lopez NE, Peterson CY, Ramamoorthy SL, McLemore EC, Sedrak MF, Lowy AM, Horgan S, Talamini MA, Sicklick J. Single-incision laparoscopic surgery through an ostomy site: a natural approach by an unnatural orifice. Surg Laparosc Endosc Percutan Tech. 2015 Feb; 25(1):74-8. PMID: 24743670.
        View in: PubMed
      20. Barajas-Gamboa JS, Acosta G, Savides TJ, Sicklick J, Fehmi SM, Coker AM, Green S, Broderick R, Nino DF, Harnsberger CR, Berducci MA, Sandler BJ, Talamini MA, Jacobsen GR, Horgan S. Laparo-endoscopic transgastric resection of gastric submucosal tumors. Surg Endosc. 2015 Aug; 29(8):2149-57. PMID: 25303921.
        View in: PubMed
      21. Ma GL, Murphy JD, Martinez ME, Sicklick J. Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):298-302. PMID: 25277795.
        View in: PubMed
      22. Burgoyne AM, Somaiah N, Sicklick J. Gastrointestinal stromal tumors in the setting of multiple tumor syndromes. Curr Opin Oncol. 2014 Jul; 26(4):408-14. PMID: 24840526.
        View in: PubMed
      23. Grigorian A, Ponsford Tipps AM, Derweesh IH, Boles SG, Sicklick J. Pelvic mass after prostatectomy. JAMA Surg. 2014 Jul 1; 149(7):741-2. PMID: 24871499.
        View in: PubMed
      24. Grigorian A, Sicklick J, Kingham TP. International surgical residency electives: a collaborative effort from trainees to surgeons working in low- and middle-income countries. J Surg Educ. 2014 Sep-Oct; 71(5):694-700. PMID: 24776855.
        View in: PubMed
      25. Fanta PT, Sicklick J, Betz BL, Peterson MR. In Vivo Imatinib Sensitivity in a Patient With GI Stromal Tumor Bearing a PDGFRA Deletion DIM842-844. J Clin Oncol. 2015 Mar 10; 33(8):e41-4. PMID: 24638008.
        View in: PubMed
      26. Tran Cao HS, Lopez N, Chang DC, Lowy AM, Bouvet M, Baumgartner JM, Talamini MA, Sicklick J. Improved perioperative outcomes with minimally invasive distal pancreatectomy: results from a population-based analysis. JAMA Surg. 2014 Mar 1; 149(3):237-43. PMID: 24402232.
        View in: PubMed
      27. Sicklick J, Leonard SY, Babicky ML, Tang CM, Mose ES, French RP, Jaquish DV, Hoh CK, Peterson M, Schwab R, Lowy AM. Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. J Transl Med. 2014; 12(1):41. PMID: 24507750.
        View in: PubMed
      28. Magistri P, Leonard SY, Tang CM, Chan JC, Lee TE, Sicklick J. The glypican 3 hepatocellular carcinoma marker regulates human hepatic stellate cells via Hedgehog signaling. J Surg Res. 2014 Apr; 187(2):377-85. PMID: 24439425.
        View in: PubMed
      29. Metildi CA, Tang CM, Kaushal S, Leonard SY, Magistri P, Tran Cao HS, Hoffman RM, Bouvet M, Sicklick J. In Vivo Fluorescence Imaging of Gastrointestinal Stromal Tumors Using Fluorophore-Conjugated Anti-KIT Antibody. Ann Surg Oncol. 2013 Dec; 20 Suppl 3:693-700. PMID: 23943029.
        View in: PubMed
      30. Sicklick J, Lopez NE. Optimizing surgical and imatinib therapy for the treatment of gastrointestinal stromal tumors. J Gastrointest Surg. 2013 Nov; 17(11):1997-2006. PMID: 23775094.
        View in: PubMed
      31. Bouvet M, Sicklick J. Management of abdominal malignancies: updates from the International Association of Surgeons, Gastroenterologists and Oncologists. Expert Rev Anticancer Ther. 2013 Apr; 13(4):395-7. PMID: 23560834.
        View in: PubMed
      32. Hemming AW, Mekeel KL, Zendejas I, Kim RD, Sicklick J, Reed AI. Resection of the liver and inferior vena cava for hepatic malignancy. J Am Coll Surg. 2013 Jul; 217(1):115-24; discussion 124-5. PMID: 23376028.
        View in: PubMed
      33. Eghtedari M, Sicklick J, Kono Y, Peterson MR, Santillan CS. Unusual imaging profile of a solitary splenic lymphangioma. Acta Radiol Short Rep. 2012; 1(8). PMID: 23986850.
        View in: PubMed
      34. Sicklick J. Correcting the misnomers of epithelial-mesenchymal relations. J Surg Res. 2013 Jun 1; 182(1):36-9. PMID: 22480829.
        View in: PubMed
      35. Lawson JD, Sicklick J, Fanta PT. Gastric cancer. Curr Probl Cancer. 2011 May-Jun; 35(3):97-127. PMID: 21635986.
        View in: PubMed
      36. Learn PA, Sicklick J, DeMatteo RP. Randomized clinical trials in gastrointestinal stromal tumors. Surg Oncol Clin N Am. 2010 Jan; 19(1):101-13. PMID: 19914562.
        View in: PubMed
      37. Sicklick J, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS, Diehl AM. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis. 2006 Apr; 27(4):748-57. PMID: 16339184.
        View in: PubMed
      38. Kakkis JL, Sicklick J, Gomes A, Cohen B, Quiñones-Baldrich WJ. Azygous vein to right atrium bypass graft in a patient with idiopathic fibrosing mediastinitis and symptomatic superior and inferior vena cava obstructions. J Vasc Surg. 2002 Nov; 36(5):1071-5. PMID: 12422122.
        View in: PubMed